The use of PHT in critically ill patients is complicated by its complex pharmacokinetics and adverse events. Levetiracetam (LEV) is a chemically unrelated AED that has linear pharmacokinetics and is not hepatically metabolized. Its efficacy has been demonstrated in a wide variety of seizure types and status epilepticus. 10 In an intensive care unit or other inpatient setting, therapy can be initiated at a therapeutic dose without risk of AED hypersensitivity syndrome. These favorable properties of LEV suggest that it may have a unique role in patients with SAH to prevent seizures and minimize adverse events. The purpose of this study was to determine the utility and tolerability of LEV in patients with SAH, and see how it compares to PHT.
Methods
All patients admitted to Duke University Medical Center with non-traumatic SAH between January 1, 2002 and June 30, 2006 were considered for enrollment in this study. Charts of patients who were treated with either PHT or LEV were reviewed in detail. This study was approved by the local Institutional Review Board (IRB).
Chart review included review of admission history and physical examination. Presence of clinical seizures was noted. Routine and prolonged electroencephalograms (EEG) were also reviewed when available to document frequency of seizures. Utility of the AED was determined by noting whether breakthrough clinical seizures occurred.
Adverse events and whether the AED was switched due to these adverse events were noted. In particular the adverse events evaluated in detail included elevation of transaminase levels, thrombocytopenia, unexplained fever, rash, and worsening mental status. Any elevation of transaminase levels was identified, but elevations that were twice the upper limit of normal were specifically noted. Platelet count of less than 100,000 mm 3 and a fever of greater than 38 8C were also noted. Worsening confusion or level of alertness was considered worsening mental status. Complaints of nausea, vomiting, or diarrhea were noted as gastrointestinal disturbance. The AED dose and plasma concentration and renal function tests results were also noted when available. Discharge summaries and first follow-up neurology or neurosurgery clinic evaluations were reviewed to determine whether AED adverse events had resolved. Only patients that had at least one follow-up visit were included. The frequency with which the AED needed to be changed and occurrence of adverse events were compared between the PHT and LEV groups using Chi-square tests.
Results
A total of 176 patients, 113 women, with SAH were enrolled in this study. The mean age of the patients was 58.2 (AE15.6) years. In all patients the SAH was secondary to rupture of an intracranial aneurysm. The site of the aneurysms is presented in Table 1 . Aneurysms of the anterior communicating artery were the most common, occurring in 59 (33.5%) of patients. The Hunt and Hess grade was 3 or less in 111 (63%) patients, grade 4 in 51 (29%) patients, and grade 5 in 14 (8%) patients. PHT and LEV were the only AED used in this series of patients. All patients received PHT first, and LEV was used only if PHT resulted in adverse events. The PHT loading dose was 20 mg/kg and maintenance dose was 5-7 mg/kg/day. The mean plasma concentration of PHT was 16 (AE6.1) mcg/mL. LEV was starting without a loading dose at 1500 mg twice a day. Plasma concentrations for LEV were not available.
All patients were initially treated with PHT within 24 h of symptom onset. Five (2.8%) patients had one or more clinical seizures at presentation before administration of PHT. Clinical seizures did not occur in any patient after initiation of AED therapy until at least their first follow-up. Either routine or prolonged EEG was obtained in only 8 (4.5%) patients. Prolonged EEGs were 24 h in length. Five of these EEGs were performed on patients who had clinical seizures at presentation; these patients were on PHT. Two additional patients being treated with PHT and one being treated with LEV had an EEG because of worsening mental status. None of the EEGs showed electrographic seizures or interictal epileptiform activity.
Seventy (39.8%) of the PHT-treated patients were subsequently switched to LEV. The switch occurred after a mean of 3.8 days after start of treatment with PHT, with all patients having been switched by day 10. Of these patients, 57 (81.4%) patients were switched because of suspected PHT induced adverse events. These included elevated transaminase levels, thrombocytopenia (platelet count of less than 100,000 per mm 3 ), unexplained fever (temperature greater than 38 8C), and rash ( Table 2 ). All patients with thrombocytopenia, unexplained fever, and rash were switched to LEV, however only 23 of the 53 (43.4%) patients with elevated transaminase levels were switched. These 23 patients had transaminase elevation greater than twice normal. Another 13 (18.6%) patients experienced gastrointestinal disturbance or worsening mental status and were switched to LEV. The association of these adverse events with PHT was considered uncertain; however a change in AED occurred regardless. While on LEV, none of the 70 patients had clinical seizures. All 56 patients who were switched to LEV because of elevated transaminase levels, thrombocytopenia, unexplained fevers, or rash had resolution of these adverse events by the time they were discharged from the hospital or by the first follow-up clinic visit (14-41 days after discharge). The frequency of the first three adverse events was significantly higher in the PHT group compared to the LEV groups ( Table 2) . Of the 4 patients with gastrointestinal disturbance prompting the change in AED to LEV, 3 (75%) improved. Worsening mental status prompted a change in the AED in 9 patients; 6 (66.7%) patients improved after being switched to LEV. One patient continued to have GI disturbance and 3 continued to have worsened mental status. It is possible that LEV may have caused these adverse effects in 4 (5.7%) patients. All patients continued to take PHT or LEV at least until first follow-up.
Discussion
In this retrospective study, patients with non-traumatic SAH did not have breakthrough clinical seizures after treatment with PHT or LEV. However, patients treated with PHT had more frequent adverse events consisting of elevated transaminase levels, thrombocytopenia, and unexplained fevers. In 39.8% of patients, PHT had to be discontinued because of adverse events; in these patients LEV was used instead. Serious adverse events leading to discontinuation of LEV were not seen.
Seizures are a complication of SAH. Variables that increase the incidence of seizures after SAH include high grade, age less than 50 years, rupture of a middle cerebral artery aneurysm, intracerebral hematoma, blood in the quadrigeminal cistern, persistent neurological deficit, and re-bleeding. 11 In older studies, seizures were reported to occur in up to 26% of patients with aneurismal SAH. 12 However, more recent studies noted that between 5 and 11% of patients develop seizures around the time of the hemorrhage.
5,13,14
The declining incidence of seizures has been attributed to improved NICU care and the routine use of prophylactic AED. In the present series, only 2.8% of patients had seizures. All these occurred at onset of the SAH and prior to institution of AED therapy. The relatively low incidence of seizures may be due to the routine use of prophylactic AED. Whether AED should be used prophylactically in all patients presenting with SAH is debated. Since the incidence of seizures in this patient population has diminished considerably in the last 20 years, some investigators have suggested that routine use of prophylactic AED is not justified.
14 However, others have suggested that the incidence of nonconvulsive seizures detected with continuous EEG monitoring is as high as 19% in patients with SAH. 15 Moreover, the prognosis is worse in patients who have seizures. 4, 5, 16, 17 The Stroke Council of the American Heart Association notes that seizures may result in neuronal injury and further destabilization of critically ill patients and must be treated aggressively. 18 Moreover, they and others suggest that
prophylactic AED therapy with PHT should be considered. 2, 18 All patients presenting to the NICU at Duke University Medical Center with SAH are prophylactically treated with PHT initially. AED use is typically continued for at least 6 months. During the time period in which this study was conducted, continuous EEG monitoring was not routinely used to monitor SAH patients, thus potentially underestimating the frequency of seizures. Several recent studies have raised doubts about whether PHT is the best AED to use for prevention of seizures in critically ill patients with SAH. Higher PHT dose was found to result in worse neurologic and cognitive outcomes in SAH survivors. 19 PHT may also interfere with the metabolism of nimodipine, which is commonly used to minimize vasospasm. Nimodipine is metabolized by the cytochrome P-450 isozyme of the hepatic microsomal enzyme system. This system is induced by PHT, thus increasing the metabolism of nimodipine. 20 This may leave patients more susceptible to vasospasm from lower nimodipine concentration. 21, 22 Since evaluation of vasospasm was not a focus of this study, it is not certain whether patients treated with PHT in this study had this complication more often. Unexplained fever may occur with PHT, which may worsen prognosis. 23 Finally, the use of PHT in the NICU is challenging due to frequent adverse events, a narrow therapeutic range, nonlinear pharmacokinetics, and frequent monitoring of total and free levels, especially during vasospasm. 13, 24 Many of the issues complicating the use of PHT in critically ill patients were noted in this study as well. Elevation of transaminase levels, thrombocytopenia, unexplained fevers, and rash occurred commonly in patients treated with PHT. Though not a focus of the study, it was noted that the dose of PHT was frequently changed to maintain an appropriate plasma concentration. Nimodipine plasma concentration was not available in this study, so whether PHT resulted in increased clearance of this medication is unclear.
LEV is a novel AED whose exact mechanism of action is unknown. Recent evidence shows that it binds to the synaptic vesicle protein 2A (SV2A), which is involved with neurotransmitter release from nerve cells. 25, 26 Additionally, LEV also has indirect effects on gamma amino butyric acid (GABAergic) neurotransmission, modulates potassium and high voltage calcium currents, and influences expression of genes associated with kindling. 27 It has linear pharmacokinetics with low intra-and inter-subject variability. The bioavailability of LEV is not affected by food, it not protein-bound and does not affect the protein binding of other drugs, and its volume of distribution is close to the volume of intra and extra-cellular water. 28, 29 LEV has also been shown to be neuroprotective in the animal models of SAH, closed head injury, and self-sustaining status epilepticus. 30, 31 The efficacy of LEV has been demonstrated in partial and generalized seizures as well as status epilepticus. 10, 32 Many of the patients in this study received the oral formulation of LEV, which is difficult to administer in critically ill patients. In the last few years, intravenous LEV has become available, and its administration has become much easier and quicker in the NICU. LEV has been used instead of PHT with favorable results in critically ill patients. [33] [34] [35] [36] Patients with acute brain injury and after supratentorial neurosurgery were noted to have problems similar to those discussed above when treated with PHT. 33, 35 Switching these patients to LEV resulted in fewer complications.
The main limitation of this study is that it was retrospective and relatively small in size with unequal groups. When comparing two AED, a prospective, randomized trial would provide the most robust data. Such a trial is difficult to perform because of the urgency of treatment of SAH patients and issues surrounding informed consent in patients with worsening mental status. A retrospective analysis, such as this one, provides preliminary data suggesting the utility of LEV in this patient population and may lead to further studies. Details of PHT and LEV serum levels were not analyzed in this study. This was because the focus of the study was whether PHT was discontinued or not, not how difficult it was to maintain consistent levels. This study also does not address the incidence of seizures in SAH acutely and long term and whether prophylactic AED therapy should be used in every patient. Drugs other than PHT and LEV were also not evaluated. Though valproic acid (VPA) has been reported to be useful in SAH, it was not used in any patient in this series. 21, 22 How VPA would compare to LEV cannot be answered by this study.
Seizures are a complication of SAH. PHT is used commonly to prevent seizures in the acute phase of management. The complicated pharmacokinetics, interactions with other commonly used drugs, and adverse effects of PHT often necessitate changing therapy. LEV appears to be well tolerated in patients with SAH, has linear pharmacokinetics, no significant drug-drug interactions, lacks many of the side effects of PHT, and is available in an intravenous formulation. It may be reasonable to consider LEV for prophylactic treatment of seizures in patients presenting with SAH.
